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P-Type Natriuretic Peptide and
he Risk of Cardiovascular Events
nd Death in Patients With Stable Angina
esults From the AtheroGene Study
enate Schnabel, MD,* Edith Lubos, MD,* Hans J. Rupprecht, MD,* Christine Espinola-Klein, MD,*
hristoph Bickel, MD,§ Karl J. Lackner, MD,† François Cambien, MD,‡ Laurence Tiret, PHD,‡
homas Münzel, MD, FAHA,* Stefan Blankenberg, MD*
ainz and Koblenz, Germany; and Paris, France
OBJECTIVES The aim of this study was to assess the predictive value of the cardiac hormone B-type
natriuretic peptide (BNP) for long-term outcome in a large cohort of stable angina patients.
BACKGROUND Recent data suggest a role of BNP in stable ischemic heart disease beyond its known value in
heart failure and acute coronary syndromes.
METHODS In 1,085 patients with coronary artery disease (CAD) baseline levels of BNP were
prospectively associated with cardiovascular (CV) events during a mean follow-up of 2.5
years.
RESULTS BNP concentrations were significantly elevated in patients with future CV events (median
[25th/75th interquartile range] 119.2 [43.6/300.4] pg/ml vs. 36.2 [11.3/94.6] pg/ml; p 
0.001). Kaplan-Meier survival analysis showed a stepwise decrease in event-free survival
across quartiles of BNP baseline concentration (plog rank  0.001). Patients in the highest
quartile revealed a 6.1-fold increased risk (p  0.001) compared to patients in the lowest
quartile after adjustment for potential confounders. For a cut-off value of 100 pg/ml, an
independently increased risk of adverse outcome (hazard ratio [HR] 4.4; p  0.001) could be
demonstrated. One standard deviation (SD) decrease in ejection fraction implied the most
prominent increase in risk of future CV events (HR 1.69; p  0.001) followed by one SD
increase in BNP (HR 1.53; p  0.001). The highest prognostic accuracy could be
demonstrated for BNP (area under the curve 0.671).
CONCLUSIONS The data of this large group of CAD patients provide independent evidence that BNP is a
strong predictor of cardiovascular risk in patients with stable angina independent of left
ventricular systolic performance and known risk factors. (J Am Coll Cardiol 2006;47:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.039552–8) © 2006 by the American College of Cardiology Foundation
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Uhe degree of cardiac neurohormonal activation as indi-
ated by B-type natriuretic peptide (BNP) has been exten-
ively investigated in cardiac disease, primarily in mechanis-
ic disorders of cardiac function. As a hormone indicator of
yocardial stretch (1) BNP is an excellent marker of heart
ailure and has already entered international guidelines. Its
eliable characteristics as a biomarker have spurred further
nvestigations in other cardiovascular disease entities. In-
eed, there is an increasing body of evidence for the concept
hat BNP might be an indicator of hypoxia and ischemia
tself which may result in myocyte stress under ischemic
onditions despite constancy in measurable hemodynamic
arameters (2–4). For patients with acute coronary syn-
romes, impressive data have been generated for BNP in the
rediction of outcome. Under these conditions BNP pro-
ides information on survival and incident heart failure
ncremental to that of anthropometric data and clinical
ariables (5,6). For long-term mortality assessment BNP
From the *Department of Medicine II and †Department of Clinical Chemistry and
aboratory Medicine, Johannes Gutenberg University, Mainz, Germany; ‡INSERM
525, Faculté de Médecine Pitié-Salpétrière, Paris, France; and the §Innere
bteilung, Bundeswehrzentralkrankenhaus, Koblenz, Germany.K
Manuscript received June 22, 2005; revised manuscript received September 13,
005, accepted September 19, 2005.as proved to be superior to necrosis markers (7). Elevated
NP obviously does not depend on acute necrosis but may
lso indicate stable states of coronary artery disease (CAD)
haracterized by repetitive microischemia under stress with-
ut significant rise of creatine kinase or troponins (8).
There is also evidence that N-terminal B-type natriuretic
eptide (Nt-proBNP), the inactive fragment of the pro-
ormone, might also be a robust indicator of cardiovascular
isk in patients with stable coronary disease (9–13).
The aim of the current study was to examine the prognostic
mpact of BNP in a large group of consecutively enrolled
table angina patients on short-term as well as long-term
ardiovascular (CV) outcome to evaluate the potential
linical applicability of BNP measurements in CAD.
ETHODS
uring the enrollment phase 1,085 consecutive patients
resenting with stable angina and at least one stenosis
30% in the larger coronary arteries entered the observa-
ional AtheroGene registry at the two recruitment centers:
epartment of Medicine II of the Johannes Gutenberg
niversity, Mainz, and the Bundeswehrzentralkrankenhaus,
oblenz, Germany.
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February 7, 2006:552–8 BNP and Cardiovascular Risk in Stable AnginaFurther details on the concept of the AtheroGene study
ave been previously described (14). In the present sub-
tudy, exclusion criteria were clinical signs of instability
unstable angina Braunwald classification class B or C, acute
T-segment elevation, and non–ST-segment elevation myo-
ardial infarction). Further reasons for exclusion were clin-
cal or echocardiographic signs of severe heart failure and
dditional known hemodynamically relevant cardiac abnor-
alities which might generate myocyte stress in addition to
vert CAD, including severe valvular heart disease, surgery
r trauma within the previous month, known cardiomyop-
thy, manifest carcinoma, chronic inflammatory disease
tates and febrile conditions, and use of oral anticoagulant
herapy within the previous four weeks. These exclusion
riteria were met by up to 30% of the eligible patients.
The history of classic risk factors was assessed as follows.
atients who had received antihypertensive treatment or
ho had received a diagnosis of hypertension (blood pres-
ure above 160/90 mm Hg) were considered to have hyper-
ension. Patients were classified as currently smoking, as
aving smoked in the past (if they had stopped more than 4
eeks and less than 40 years earlier), or as never having
moked (if they had never smoked or had stopped 40 or
ore years earlier). Patients who were receiving dietary
reatment or medication for diabetes or who presented with
asting blood glucose levels above 125 mg/dl were defined as
iabetic.
In 769 patients, left ventricular ejection fraction (EF) was
etermined by angiography and off-line analysis according
o the area-length method (15).
Among the 1,085 patients, survival status remained
nknown in 11 subjects (1%) who were lost during follow-
p, and the data of 2 patients for whom EF was not
vailable were excluded from analysis owing to a BNP
oncentration over 1,500 pg/ml, which might indicate
evere heart failure. The final study population consisted of
,072 individuals who were followed over a median of 2.5
.2 years (skewness1). During this time, 35 cardiovascular
eaths, 15 deaths from other causes, and 17 nonfatal
yocardial infarctions were registered. The primary end
oint was nonfatal myocardial infarction and cardiovascular
eath. Follow-up information was obtained from patient
harts and death certificates. All data were evaluated by an
ndependent adjudication committee consisting of experi-
nced physicians who were blinded to BNP concentrations.
The study was approved by the local ethics committee of the
Abbreviations and Acronyms
BNP  B-type natriuretic peptide
CAD coronary artery disease
CRP  C-reactive protein
CV  cardiovascular
EF  left ventricular ejection fraction
HR  hazard rationiversity of Mainz. All patients were Caucasian. Participa- sion was voluntary, and patients were enrolled after written
nformed consent was obtained.
aboratory methods. Blood samples were drawn under
tandardized conditions before coronary angiography was
erformed when the patients entered the catheterization lab
fter a minimum 12-h fast. Serum lipids and creatinine were
easured immediately by routine methods; low-density
ipoprotein was calculated by the Friedewald formula. For
ll other biomarkers measured in the study population,
lasma and serum were stored at 80°C immediately after
entrifugation.
Plasma B-type natriuretic peptide was determined using a
uorescence immunoassay (Biosite, San Diego, California).
he detection limit reported is 5 pg/ml, the upper limit
,000 pg/ml. The assay has an interassay coefficient of
ariation of near 10%, and a recovery of 100% of added
eptide was found. Cross-reactivity with other natriuretic
eptides is negligible (16). C-reactive protein (CRP) was
etermined by a highly sensitive, latex particle-enhanced
mmunoassay (detection range 0 to 20 mg/l; Roche Diag-
ostics, Mannheim, Germany).
tatistical considerations. The mean values and propor-
ions of baseline cardiovascular risk factors, clinical vari-
bles, and biomarkers were calculated for study participants
ccording to occurrence of future cardiovascular events. The
tatistical significance of differences between the means for
he two subgroups was assessed with Student t test, and the
ignificance of differences in proportions was tested with the
hi-squared statistic. Variables with a skewed distribution
ere presented as medians and Wilcoxon rank sum test was
pplied. Patients were divided into four subgroups on the
asis of their BNP level at the time of enrollment. The
umulative event plots according to quartiles of BNP
oncentration were estimated by the Kaplan-Meier method
nd compared with use of the log rank test. All survival
nalyses were conducted for the primary end point of
onfatal myocardial infarction and cardiovascular death.
ata from patients who died from causes not related to
ardiovascular disease were censored at the time of death.
azard ratios for future CV events were estimated by Cox
egression models adjusted for potential confounders. All
odels included the adjustment for age and sex. Further
djustment was performed for classic risk factors (body mass
ndex, high-density lipoprotein cholesterol levels, a history of
ypertension, diabetes, and smoking). The second model
urther comprised clinical variables such as presence of
ultivessel disease and cardiac medication with
ngiotensin-converting enzyme inhibitors and statins and
he inflammatory marker CRP. The final analyses included
F into the regression models. To compare the predictive
ower of BNP to known risk measures in stable angina
atients, the hazard ratios (HR) found for one standard
eviation increase of BNP, CRP, fibrinogen, and EF were
resented for two Cox regression models. A backward
tepwise Cox regression approach was taken for the multi-
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BNP and Cardiovascular Risk in Stable Angina February 7, 2006:552–8ariate analyses, with p  0.10 as the critical value for
ntering and excluding variables in the model.
The HR and 95% confidence interval (CI) are reported.
he p values are two-sided; a p value of less than 0.05 was
onsidered to indicate statistical significance. All computa-
ions were carried out with SPSS software 11.5 (SPSS Inc.,
hicago, Illinois).
ESULTS
he mean age of the study population was 61.6 9.4 years,
nd 79.7% were male. During follow-up, 52 CV events were
ocumented (17 nonfatal myocardial infarctions and 35 CV
eaths). BNP levels exhibited a skewed distribution with a
Table 1. Baseline Characteristics of the Study
Cardiovascular Events
Characteristic
P
Ca
Age, yrs
Male, %
Traditional risk factors
Body mass index, kg/m2
History of hypertension, %
History of diabetes, %
Fasting blood glucose, mg/%
Cigarette smoking, %
Never
Ex-smokers
Current smoking
Lipid status
Total serum cholesterol, mg/dl
LDL cholesterol, mg/dl
HDL cholesterol, mg/dl
Clinical variables
Number of diseased vessels, %
1 vessel
2 vessels
3 or more vessels
Heart rate at entry, beats/min
Systolic blood pressure at entry, mm Hg
Diastolic blood pressure at entry, mm Hg
MAP at entry, mm Hg
PTCA at entry, %
Left ventricular ejection fraction, %
Medication, %
ACE inhibitor
Statin
Beta-blocker
Diuretics
Metabolic variables
BUN
Biomarkers
Fibrinogen, mg/dl
Plasma B-type natriuretic peptide, pg/ml
Plasma C-reactive protein, mg/l
Serum creatinine, mg/dl
Data presented are percentage of patients, mean  standard
variables. For normally distributed variables, p values were c
computed with the Wilcoxon rank sum test for the differenc
test was used. Invasive data were available for 942 (86.2%
ventricular angiography was available for 769 individuals.BUN  blood urea nitrogen; HDL  high-density lipoprotei
pressure; PTCA  percutaneous transluminal coronary angioplastyedian (25th/75th interquartile range) of 38.3 (11.8/
00.35) pg/ml. BNP concentration was significantly higher
n patients who suffered from future CV events than in
hose who remained free of adverse events (119.2 [43.6/
00.4] vs. 36.2 [11.3/94.6] pg/ml; p  0.001). Baseline
evels of BNP in patients who died from non-CV causes
n  15) were not significantly different from those in
vent-free individuals (45.5 [5.0/171.4] vs. 36.1 [11.5/93.7]
g/ml; p  0.83). For overall mortality (n  50) it could be
emonstrated that BNP concentrations were significantly
igher in the CV event group (119.2 [20.3/315.3] vs. 36.31
11.6/97.8] pg/ml in event-free subjects; p  0.001). In
able 1 the baseline characteristics of the study population
lation According to Occurrence of
ts Without
ascular Event
1,020
Patients With
Cardiovascular Event
n  52 p Value
.6  9.4 61.7  10.4 0.93
80.4 65.4 0.009
.7  14.8 27.9  21.0 0.72
80.4 71.2 0.11
21.2 40.4 0.001
93/116.5) 108.5 (94.8/128.3) 0.12
0.14
37.0 28.8
46.4 44.2
16.7 26.9
165/224) 203 (166/243) 0.29
95/149) 124 (97/169) 0.37
41/57) 46 (37.3/57.8) 0.22
0.74
28.0 25.0
31.6 36.5
40.4 38.5
.4  15.2 77.0  14.7 0.16
.0  67.1 138.2  31.9 0.68
.7  12.0 69.6  11.6 0.88
.3  15.3 95.7  17.0 0.99
27.1 22.0 0.72
.2  14.8 56.7  21.0 0.001
49.6 48.1 0.83
55.5 48.1 0.29
63.6 55.8 0.25
30.8 42.3 0.08
15.0/30.8) 24.9 (15.9/33.1) 0.1
262/365) 352 (316/399) 0.001
11.3/94.6) 119.2 (43.6/300.4) 0.001
1.2/4.9) 4.28 (1.9/9.1) 0.001
0.83/1.06) 1.02 (0.82/1.21) 0.11
on, or median and 25th/75th interquartile range for skewed
ted with Student t test; for skewed variables, p values were
edians. For comparison of categorical variables a chi-square
jects. Left ventricular ejection fraction determined by leftPopu
atien
rdiov
n 
61
27
102 (
195 (
121 (
48 (
73
138
69
95
65
19.6 (
309 (
36.2 (
2.3 (
0.94 (
deviati
ompu
e in m
) subn; LDL  low-density lipoprotein; MAP  mean arterial
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February 7, 2006:552–8 BNP and Cardiovascular Risk in Stable Anginaccording to the occurrence of future CV events are out-
ined. In the event group, the proportion of females was
igher and diabetes was significantly more often seen. Left
entricular ejection fraction was lower in subjects with
dverse outcome, although the mean value was within the
ormal range in both groups. Both groups did not relevantly
iffer in general hemodynamic parameters measured inva-
ively at study entry. Of the inflammatory biomarkers
etermined, CRP and fibrinogen were higher in the event
roup, as expected (p 0.001 for both). Age at baseline was
ot significantly different in both groups.
igure 1. Kaplan-Meier curves showing the cumulative incidence of
ardiovascular events during follow-up according to quartiles of BNP
lasma levels. Quartile ranges: Q1 11.84; Q2 11.84 to 38.30; Q3 38.30
o 100.35; Q4 100.35 pg/ml. BNP  B-type natriuretic peptide.
Table 2. Hazard Ratios for Quartiles of Baseli
Lowest Quartile
Quartile
Q1
n  268
Q
n 
BNP (pg/ml) 11.8 11.8–
Cardiovascular events, n 5 7
Cardiovascular events, % 1.9 2.
Age- and gender-adjusted
Hazard ratio 1 1.
95% CI — 0.52–
p value — 0.
Risk factor-adjusted*
Hazard ratio 1.0 1.
95% CI — 0.55–
p value — 0.
Fully adjusted†
Hazard ratio 1.0 1.
95% CI — 0.38–
p value — 0.
*Risk factor adjustment included age and gender, body m
continuous variables. The following parameters entered the m
smoking status, angiotensin-converting enzyme inhibitor
†Additionally adjusted for ejection fraction. Because of miss
of data from only 769 patients.
BNP  B-type natriuretic peptide; CI  confidence interval; QFigure 1 shows the Kaplan-Meier survival curves accord-
ng to quartiles of baseline BNP concentration. The unad-
usted event-free survival decreased in a stepwise fashion
cross increasing quartiles (plog rank  0.001). A threshold
ffect appeared for patients in the upper quartile, where a
apid decline in survival rate can be observed. To assess the
ndependent strength of BNP for cardiovascular risk pre-
iction in comparison with known cardiovascular risk fac-
ors, three Cox regression models were developed for log-
ransformed BNP concentration. The age- and gender-
djusted HR showed a 3.36-fold (95% CI 2.01 to 5.61; p 
.001) increased risk. After adjustment for risk factors (HR
.16, 95% CI 1.82 to 5.48; p  0.001) and EF (HR 2.87,
5% CI 1.47 to 5.58; p 0.002), which was available in 769
ubjects, this association remained independently signifi-
ant. These models were similarly applied to the quartile
nalysis of BNP (Table 2). For patients in the upper quartile
f BNP baseline concentration, an 8.1-fold (p  0.001)
ncreased risk for future CV events could be observed in
omparison with subjects in the first quartile. This predic-
ive power was only slightly diminished after the adjustment
or potential confounders such as classic risk factors, clinical
ariables, CRP, and even EF.
Owing to the observation of the fourth quartile border of
00.35 pg/ml, a cut-off value of 100 pg/ml was chosen and
everal Cox regression models were examined for patients
ho presented with BNP concentrations above this value at
nrollment (Fig. 2). In comparison with patients whose
aseline levels did not exceed this concentration, these
ubjects revealed a 4.4-fold (95% CI 2.4 to 7.8; p  0.001)
ncreased risk of adverse outcome. This association re-
ained stable even after full adjustment for classic risk
actors, clinical variables, CRP, and EF.
NP Concentration in Comparison With the
Q3
n  268
Q4
n  268 p Value
38.3–100.3 100.3
12 28
4.5 10.4
2.85 8.14 0.001
0.99–8.23 2.98–22.22
0.52 0.001
3.13 7.77 0.001
1.07–9.15 2.73–22.1
0.037 0.001
2.34 6.10 0.001
0.74–7.36 2.0–18.57
0.15 0.001
dex, C-reactive protein, and high-density lipoprotein as
s dichotomized variables: a history of hypertension, diabetes,
py, statin therapy, and presence of multivessel disease.
ues for left ventricular ejection fraction, this model consistsne B
2
268
38.3
6
67
5.29
39
77
5.69
34
34
4.82
65
ass in
odels a
thera
ing val quartile.
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BNP and Cardiovascular Risk in Stable Angina February 7, 2006:552–8The 13 clinical and laboratory variables that predicted
p  0.1) univariate risk were entered into multivariate Cox
egression analyses (Table 3). One SD increase of BNP
HR 1.4, 95% CI 1.1 to 1.7; p  0.004) was selected as an
ndependent predictor of cardiovascular events, together
ith one SD decrease in EF (HR 1.4, 95% CI 1.1 to 1.9;
 0.012). The final model further included female gender
HR 0.5, 95% CI 0.2 to 1.0; p  0.04) and statin therapy
HR 0.6, 95% CI 0.3 to 1.1; p  0.08). These results did
ot differ significantly when CRP was also introduced into
he initial model.
To further pose BNP into relation to known risk markers
n patients with manifest CAD, the predictive power of one
D increase in BNP levels, CRP, and fibrinogen and one
D decrease in EF are illustrated in Figure 3. In this group
f patients without overt systolic heart failure, the decrease
n left ventricular function implied the most prominent
ncrease in risk of future CV events (HR 1.69; p  0.001),
ollowed by BNP (HR 1.53; p  0.001), fibrinogen (HR
.49; p  0.001), and CRP (HR 1.22; p  0.002). Similar
elations were found after adjustment for classic risk factors
nd clinical variables. The highest prognostic accuracy could
e demonstrated for BNP (maximum area under the re-
eiver operating characteristics curve of 0.671) and the
owest value for EF (0.623). When analyses were performed
n the subgroup of patients (n  769) for whom EF data
ere available, the results were similar.
ISCUSSION
his large-scale prospective study demonstrates the high
rognostic value of BNP for long-term outcome in stable
igure 2. Hazard ratio and 95 percent confidence interval (CI) of cardio-
ascular events associated with BNP concentrations above a chosen cut-off
alue of 100 pg/ml, the border of the upper quartile in this cohort being
00.35 pg/ml. Adjustment was performed in four consecutive models as
utlined. The traditional risk factors (RFs) (models 2 to 4) comprised age,
ender, a history of hypertension, diabetes, smoking status, body mass
ndex, and high-density lipoprotein (the last two parameters entered the
odel as continuous variables). Presence of multivessel disease and therapy
ith angiotensin-converting enzyme inhibitors and statins entered the Cox
egression analysis as clinical variables (models 2 to 4). BNP  B-type
atriuretic peptide; CRP  C-reactive protein; EF  angiographically
etermined left ventricular ejection fraction.ngina patients in a Caucasian cohort of consecutive CAD
i
pubjects independent of left ventricular systolic function and
nflammatory biomarkers.
Evidence is accumulating that BNP may serve as an
ndicator of ischemic disease. Apart from its strong diag-
ostic and prognostic characteristics in patients with left
entricular dysfunction (11,17), ischemia seems to be a trigger
f BNP expression and release (2,4). In acute ischemia the
agnitude of BNP increase mirrors the extent of jeopar-
ized myocardium and the tendency toward adverse remod-
ling more closely than any other current marker. It has
een shown that BNP concentration provides information
ndependent of necrosis markers and more adequately re-
ects myocardial territory at risk under acute ischemia.
imilar conditions seem to apply for reversible ischemia
nder stress testing, because the proportion of ischemic
erritory without overt necrosis is consistently reflected in
NP levels (18).
However, generalization has to be considered with cau-
ion, because BNP is not specific enough as a measure of
schemia. In community-based cohorts, a prospective asso-
iation between BNP levels and a range of CV outcomes
nd overall mortality has been reported in asymptomatic
ndividuals with BNP thresholds well below those used to
iagnose heart failure (19). In the primary prevention screening
t will be difficult to provide therapeutically clear directives
acing the multitude of causes leading to a moderate
ncrease in BNP. Under the precondition of diagnosed
AD the situation might be different.
First evidence thus suggests an advantageous role of BNP
n secondary risk stratification. BNP seems to reliably diagnose
hose patients with adverse outcome with a four-fold in-
reased risk for individuals with BNP levels elevated above
potential cut-off value of 100 pg/ml. Although median
NP concentrations in the general CAD population were
ound to be far below those observed in acute heart failure
20), the concentration to rule out heart failure might get a
ew dimension, because stable angina patients who present
ith BNP above this level were at high risk to experience an
dverse cardiovascular outcome during follow-up and
hould attract special attention.
able 3. Final Model of a Backward Multiple Stepwise
egression Analysis for Cardiovascular Risk Predictors
Variable Hazard Ratio 95% CI p Value
NP (1 SD increase) 1.36 1.11–1.68 0.004
V ejection fraction
(1 SD decrease)
1.45 1.08–1.93 0.012
emale gender 0.45 0.25–0.97 0.04
tatin intake 0.56 0.29–1.07 0.08
hirteen variables were introduced into a multiple stepwise backward regression
odel: age (dichotomized for the age of 65), gender, body mass index, a history of
ypertension, diabetes, smoking, presence of multivessel disease, cardiac medication
ACE inhibitors, statins, and beta-blocker), one standard deviation (SD) increase in
-type natriuretic peptide (BNP), high-density lipoprotein cholesterol, and one SD
ecrease in left ventricular (LV) ejection fraction. A stepwise backward regression was
alculated. p 0.1 was chosen as the critical value for entering and excluding variables
n the model. Hazard ratios and 95% confidence intervals are reported with two-tailed
robability values.
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February 7, 2006:552–8 BNP and Cardiovascular Risk in Stable AnginaFurther investigations have to be undertaken to stan-
ardize Nt-proBNP and BNP data, determine cut-off
alues, and derive therapeutic implications.
The value of additional BNP determination becomes obvi-
us in comparison with anthropometric and metabolic
ariables. B-type natriuretic peptide retained its strong
nd independent predictive power after adjustment for
ge, gender, and renal function, which are associated with
NP concentrations and are potent risk factors them-
elves (21–23). The data from our cohort of consecutive
nselected stable angina pectoris patients show that
outine applicability seems to be practicable without loss
f validity.
Importantly, the risk information provided by BNP proved
o be independent of angiographically defined severity of
AD and cardiac functional parameters, which further
nderlines the value of additional BNP determination.
ackward regression analysis revealed BNP and EF as the
trongest predictors of future CV events, which demon-
trates that risk information gained by BNP determination
s complementary and obviously incremental to systolic left
entricular performance (6).
tudy limitations. As a limitation it must be mentioned
hat for this cohort only single measurements at enrollment
an be investigated. Serial measurements of BNP concen-
igure 3. Hazard ratio associated with an increase of one standard deviati
dditionally includes traditional risk factors (a history of hypertension, diabe
arameter) and clinical variables (multivessel disease and therapy with angio
nder the receiver operating characteristics curve (AUC) are provided for
he final model included only 767 patients because of missing data for ejerations would be of great interest for elucidating effective- fess of therapeutic strategies and evaluating whether ini-
ially determined cardiac risk can be modified by therapeutic
nterventions.
Furthermore, as expected, only a small number of events
ere registered during follow-up in this intermediate-risk
opulation, which reduces statistical power. Despite the
elatively low event rate, BNP provided strong results after
djustment for known risk predictors, underlining the strength
f this novel biomarker.
onclusions. The present data support the view that BNP
ight develop into a biomarker for “many cardiac seasons”
24). Responsible for the fine tuning of cardiac homeostasis,
t is involved in a variety of cardiac abnormalities. Until its
athophysiologic background is entirely understood, an in-
reasing number of novel clinical indications and benefits can
e expected. The results of the present study, taken together
ith recent data on Nt-proBNP, provide a promising basis
or further investigations into risk stratification in stable
AD where BNP has been shown to improve prognosis
ssessment in this intermediate-risk group independent of
nd incremental to classical risk factors.
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